The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Clinical Intervention Awards, 2009SING-PD: Singing In Groups for Parkinson's Disease: A Phase I/II Study of Choral Therapy for PD-related Voice/Speech Impairment
Objective/Rationale:
To compare two forms of speech and voice therapy (one involving breathing and speech exercises and the other involving singing in groups) to see which type of therapy is better in... -
Clinical Intervention Awards, 2009Naltrexone for Impulse Control Disorders in Parkinson's Disease
Objective/Rationale:
This is the first controlled trial of an agent to treat impulse control disorders (ICDs) in Parkinson’s disease (PD). Naltrexone, which blocks opioid receptors, is FDA-approved... -
Clinical Intervention Awards, 2009Eltoprazine for Treatment of Levodopa-induced Dyskinesias
Objective/Rationale:
Researchers have identified a new potential drug target — receptors located on the serotonin neurons in the brain — for alleviation of involuntary movements, dyskinesias, in... -
MJFF Research Grant, 2009Generation of specific Lrrk2 antibodies in murine LRRK2 knockout mice
Objective/Rationale:
Several years after the discovery of mutations in the LRRK2 gene as an important cause of Parkinson’s disease, relatively little is known regarding the basic cellular function of... -
MJFF Research Grant, 2009Analysis of the Role of PPN Neurons in Postural Disturbances in a Model of Parkinson's Disease
Promising Outcomes of Original Grant:
The aim of our previous study funded by The Michael J. Fox Foundation for Parkinson’s Research was to unravel the role of non-dopaminergic lesion in gait and... -
Program-non-specific Funding, 2009Elucidating the Mechanism of Action of J3, A Neuroprotective Small Molecule Candidate to Treat Parkinson's Disease"
Objective/Rationale:
We have identified a small molecule, designated J3, which shows promising neuroprotection in an acute animal model of Parkinson’s disease. To reach our ultimate goal of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.